Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on DexCom

Share:
Related DXCM
5 Mid-Cap Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years
Good News For Apple Watch: FDA Steps Back From App Regulation
DexCom Hits 52-Week High, Robust Pipeline Key Catalyst - Analyst Blog (Zacks)

In a report published Friday, Jefferies & Company reiterated its Buy rating on DexCom (NASDAQ: DXCM), but lowered its price target from $18.00 to $16.50.

Jefferies noted, “DexCom released final 3Q revenues of $23.1mn after pre-announcing in early October with the G4 Platinum Sensor approval. The final 3Q numbers reflect a handful of one-time charges and adjustments; full year guidance was reiterated. The G4 and the subsequent pump combinations set the table for a good run.”

DexCom closed on Thursday at $13.07.

Latest Ratings for DXCM

DateFirmActionFromTo
May 2015OppenheimerMaintainsPerform
Feb 2015JefferiesMaintainsBuy
Feb 2015JP MorganMaintainsOverweight

View More Analyst Ratings for DXCM
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (DXCM)

Around the Web, We're Loving...